Allo HSCT for High Risk Hemoglobinopathies

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Intervention

Alemtuzumab(drug)

Enrollment

62 enrolled

Eligibility

55 years · All sexes

Timeline

2024 – 2032

Study locations (1)

• Masonic Cancer Center, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Complication after organ transplantation

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06512519
  Second Haplo-transplantation for Graft Failure
  Peking University People's Hospital
• RECRUITINGNANCT06512545
  Modified Second Haplo-transplantation for Graft Failure
  Peking University People's Hospital
• RECRUITINGNCT05836922
  Association Between Renal Regional Oxygen Saturation Measured by Near-InfraRed Spectroscopy and Postoperative Renal Failure After Lung Transplantation Surgery: A Pilot Study
  Assistance Publique Hopitaux De Marseille
• RECRUITINGNANCT06386198
  HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients
  University of California, San Francisco
• RECRUITINGEARLY PHASE1NCT04469842
  Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNCT05818644
  Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
  University Medical Center Groningen
• ACTIVE NOT RECRUITINGPHASE4NCT05557370
  Immunogenicity of HPV Vaccine in Transplant Recipients.
  Medical College of Wisconsin
• ENROLLING BY INVITATIONPHASE2NCT05285878
  Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
  The Methodist Hospital Research Institute

See all trials for Complication after organ transplantation →